13F Holdings
中文EN

ELVN Enliven Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1672619 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.7%
TTM EPS YoY6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-16.8%
ROA-16.4%
ROIC (approx.)-19.4%
Asset turnover—

Leverage & solvency

Liabilities / assets2.3%
Debt / equity0.00x
Current ratio45.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$85.86M$80.78M$64.57M$31.02M$38.44M
SG&A expense$33.80M$23.78M$18.95M$7.77M$13.00M
Operating income-$119.66M-$104.55M-$83.53M-$38.79M-$51.44M
Pretax income———$1.58M-$51.38M
Income tax$0$232,000$0$0—
Net income-$103.69M-$89.02M-$71.58M-$37.66M-$51.38M
EBITDA-$119.36M-$104.25M-$83.23M-$38.59M-$51.34M
EPS (basic)-1.83-1.89-2.01-12.05-2.37
EPS (diluted)-1.83-1.89-2.01-12.05-2.37
Weighted avg. shares (diluted)56.66M47.07M35.55M3.12M21.66M
Balance sheet
Cash & equivalents$98.90M$124.17M$100.19M$75.59M$110.08M
Short-term investments$363.73M$189.32M$153.01M$0$41.97M
Current assets$474.88M$318.13M$266.15M$77.75M$92.70M
PP&E, net$34,000$458,000$742,000$890,000$250,000
Total assets$476.17M$325.76M$271.87M$83.30M$93.65M
Current liabilities$16.57M$15.91M$25.89M$9.71M$7.21M
Total liabilities$16.57M$15.91M$25.96M$10.37M$7.62M
Shareholders' equity$459.60M$309.85M$245.91M-$76.83M-$42.89M
Shares outstanding59.44M48.94M41.29M3.57M26.29M
Cash flow statement
Operating cash flow-$70.30M-$73.19M-$61.27M-$32.08M-$46.77M
Capital expenditure$158,000$44,000$149,000$612,000$12,000
Free cash flow-$70.46M-$73.24M-$61.42M-$32.69M-$46.78M
Investing cash flow-$173.84M-$36.00M-$148.41M-$612,000-$1.63M
Financing cash flow$218.87M$133.16M$234.29M-$1.80M$49.10M
Depreciation & amortization$300,000$300,000$300,000$200,000$99,000
Stock-based compensation$34.02M$20.17M$12.91M$3.19M$3.85M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.